Lilly’s retatrutide cut weight by up to 28.7% and significantly reduced knee osteoarthritis pain, but dose and safety trade-offs now matter.
Eli Lilly and Company has announced successful topline results from its Phase 3 TRIUMPH-4 clinical trial evaluating retatrutide, a triple hormone receptor agonist, in adults with obesity and knee osteoarthritis. The once-weekly investigational therapy delivered significant dual benefits: an average weight loss of 28.7 percent and a 75.8 percent reduction in joint pain, measured by